Bazedoxifene
Estrogen Agonist/Antagonist — GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: bazedoxifene acetate, conbriza, TSE-424, TSE424
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Bazedoxifene is an onp drug in the Estrogen Agonist/Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Selective Estrogen Receptor Modulators. DrugCentral lists 2 molecular targets, including ESR1 and ESR2. Recorded indications include Menopausal flushing and Postmenopausal osteoporosis.
- Approval status: onp (first approved 2013 by the FDA).
- Drug class: Estrogen Agonist/Antagonist.
- Mechanism of action: Selective Estrogen Receptor Modulators.
- Molecular targets: ESR1 and ESR2 (2 listed in DrugCentral).
- Indications: Menopausal flushing and Postmenopausal osteoporosis.
- ATC code: G03CC07 (Estrogens, combinations with other drugs).
- Molecular formula: C30H34N2O3; molecular weight 470.61 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Menopausal flushing
- Postmenopausal osteoporosis
Mechanism & targets
| Mechanism of action (MoA) | Selective Estrogen Receptor Modulators |
|---|---|
| Established pharmacologic class | Estrogen Agonist/Antagonist |
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Estrogen receptor | ESR1 | modulator | IC50 9.22 |
| Estrogen receptor beta | ESR2 | modulator | IC50 8.42 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2013-10-03 | FDA | — | WYETH PHARMS PFIZER |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G03CC07 | GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › ESTROGENS › Estrogens, combinations with other drugs |
G03XC02 | GENITO URINARY SYSTEM AND SEX HORMONES › SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM › Selective estrogen receptor modulators |
Chemical structure
| Molecular formula | C30H34N2O3 |
|---|---|
| Molecular weight | 470.61 g/mol |
| CAS number | 198481-32-2 |
| InChIKey | UCJGJABZCDBEDK-UHFFFAOYSA-N |
| PubChem CID | 154257 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Bazedoxifene used for?
DrugCentral lists the following indications for Bazedoxifene: Menopausal flushing and Postmenopausal osteoporosis.
How does Bazedoxifene work?
Bazedoxifene is classified as Selective Estrogen Receptor Modulators; its molecular targets in DrugCentral include ESR1 (modulator) and ESR2 (modulator).
When was Bazedoxifene first approved?
Bazedoxifene was first approved by the FDA in 2013.
What drug class does Bazedoxifene belong to?
Bazedoxifene is in the Estrogen Agonist/Antagonist class.
What is the chemical formula of Bazedoxifene?
Bazedoxifene has the molecular formula C30H34N2O3 and a molecular weight of 470.61 g/mol.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4334 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2106615 — compound record and bioactivity
- PubChem CID 154257 — chemical identifiers
- DrugBank DB06401 — drug record
- FDA UNII Q16TT9C5BK — substance identity
- DailyMed: FDA labels for Bazedoxifene — current prescribing information (label search)
- UniProt P03372 (ESR1) — target protein
- UniProt Q92731 (ESR2) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.